| | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司第十届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 南京医药股份有限公司（以下简称"公司"）第十届董事会第三次会议于 2025 年 8 月 15 日以电话及邮件方式发出会议通知及材料，并于 2025 年 8 月 28 日以现场加通讯方式在公司 14 楼 1403 会议室召开，会议召开符合《公司法》和 《公司章程》的规定。会议由董事长周建军先生主持，应到会董事 9 人，实到会 董事 9 人，董事周建军先生、张靓先生、徐健男女士、骆训杰先生，独立董事王 春晖先生、陆银娣女士、吕伟先生现场出席了本次会议，董事陆志虹先生、Marco Kerschen 先生以通讯方式出席了本次会议。公司监事及董事会秘书列席会议。会 议经过充分讨论，以记名投票方式审议通过本次董事会全部议案。 二、董事会会议审议情况 1、审议通过《南京医药股份有限公司 2025 年半年度报告》及其摘要； （具体内容详见上海证券交易 ...

人民财讯8月29日电，南京医药（600713）8月29日晚间披露半年报，2025年上半年，公司实现营业收入 279.67亿元，同比增长2.7%；归属于上市公司股东的净利润2.91亿元，同比下降6.44%；基本每股收益 0.222元。公司拟向全体股东每10股派发现金红利1.7元(含税)。 (资料图片仅供参考) ...

格隆汇8月29日丨南京医药(600713.SH)公布2025年半年度报告，报告期实现营业收入279.67亿元，同比 增长2.70%；归属于上市公司股东的净利润2.91亿元，同比下降6.44%；归属于上市公司股东的扣除非经 常性损益的净利润2.66亿元，同比下降14.08%；基本每股收益0.222元。 ...

南京医药公告，2025年上半年营业收入279.67亿元，同比增长2.70%。净利润2.91亿元，同比下降 6.44%。 ...

南京医药股份有限公司2025 年半年度报告 公司代码：600713 公司简称：南京医药 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年半年度报告 1 / 171 南京医药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人周建军、主管会计工作负责人孙剑及会计机构负责人（会计主管人员）李菁声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司半年度未进行利润分配。 公司2024年度利润分配方案经公司2025年6月5日召开的2024年年度股东大会审议通过，以实 施权益分派股权登记日登记的总股本1,308,916,414股扣除公司回购专用证券账户中的股份280,951 股后的股份1,308,635,463股为基数，向全体股东每10股派发现金红利1.70元（含税），共计派发现 金红 ...

| 证券简称：南京医药 | 编号：ls2025-112 | | --- | --- | | 证券代码：600713 | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于公司募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意南京医药 股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕 1736 号）核准，公司向不特定对象发行可转换公司债券 10,814,910 张，每张面 值为人民币 100 元（人民币，下同），募集资金总额为人民币 1,081,491,000.00 元，扣除与发行有关的费用人民币 12,450,077.69 元（不含增值税），募集资金净 额为人民币 1,069,040,922.31 元。 上述募集资金已于 2024 年 12 月 31 日到账，毕马威华振会计师事务所（特 殊普通合伙）对本次募集资金到位情况进 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Core Viewpoint - The company has successfully completed the public leasing of its property located at 27 Yanling Lane, Qinhuai District, Nanjing, to Wangu Company, generating stable rental income over a 13-year lease term [1][2]. Group 1: Leasing Process - The company’s board approved the public leasing of the property on June 23-25, 2025, with a starting annual rent of 7.1155 million yuan [1]. - The total area for lease is 13,325.11 square meters, with a lease term of 13 years, including a 6-month rent-free period [1]. - The total expected rental income over the lease term is approximately 97.0973 million yuan, with a 5% increase in rent every three years starting from the fourth year [1][2]. Group 2: Progress of Leasing - The property was publicly listed for lease from July 16 to July 29, 2025, attracting one qualified bidder, Wangu Company [2]. - The final leasing agreement was confirmed on August 20, 2025, with the same annual rent of 7.1155 million yuan and a total lease amount of 97.0973 million yuan [2]. Group 3: Tenant Information - Wangu Company is based in Nanjing, with a registered capital of 66.6667 million yuan and operates in various sectors including enterprise management and property management [3]. - The major shareholder of Wangu Company is Jiangsu Wangu Financial Management Co., Ltd., holding 73.8% of its shares, and there is no related party relationship between the company and Wangu [4]. Group 4: Impact on the Company - The leasing of the property is expected to enhance the company's asset utilization and optimize resource allocation, providing a long-term stable rental income [4].

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its third short-term financing bond for 2024, with a total issuance amount of 50 million yuan [1] - The bond, named "24 Nanjing Pharmaceutical SCP003," has an interest rate of 1.8% and a maturity period of 269 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be approximately 50.66329 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the Interbank Market Clearing House before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the Interbank Market Clearing House of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]